High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: A randomized study

A. Veronesi, V. Zagonel, U. Tirelli, E. Galligioni, S. Tumolo, L. Barzan, M. Lorenzini, R. Comoretto, E. Grigoletto

Research output: Contribution to journalArticle

Abstract

From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dise (120 mg/m2) or low-dose (60 mg/m2) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.

Original languageEnglish
Pages (from-to)1105-1108
Number of pages4
JournalJournal of Clinical Oncology
Volume3
Issue number8
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: A randomized study'. Together they form a unique fingerprint.

Cite this